FDA Clearance Tracker · P130014-S022
Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 15, 2026
Approved
Time to decision
209 days
Received Dec 18, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130014-S022
- Device name
- Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant
- Applicant
- Stryker Leibinger GmbH & Co KG
- Applicant location
- Freiburg
- Received
- Dec 18, 2025
- Decided
- Jul 15, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130014
Device type
- Device type
- Sealant, dural (NQR)
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
The Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant are indicated for use in patients who are 13 years of age and older, as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure during cranial and spinal procedures.
Source documents
Other decisions for Stryker Leibinger GmbH & Co KG
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- RibPlate System510(k)
K261054 · Decided Jul 1, 2026 · 92 days after receipt
Device type: Plate, Fixation, Bone (HRS) · Orthopedic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.